Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Neurocognition and quality of life after reinitiating antiretroviral therapy in children randomized to planned treatment interruption.

Ananworanich J, Melvin D, Amador JT, Childs T, Medin G, Boscolo V, Compagnucci A, Kanjanavanit S, Montero S, Gibb DM; PENTA 11 Study Group.

AIDS. 2016 Apr 24;30(7):1075-81. doi: 10.1097/QAD.0000000000001011.

PMID:
26730569
2.

HIV-1 Drug Resistance and Second-Line Treatment in Children Randomized to Switch at Low Versus Higher RNA Thresholds.

Harrison L, Melvin A, Fiscus S, Saidi Y, Nastouli E, Harper L, Compagnucci A, Babiker A, McKinney R, Gibb D, Tudor-Williams G; PENPACT-1 (PENTA 9PACTG 390) Study Team.

J Acquir Immune Defic Syndr. 2015 Sep 1;70(1):42-53. doi: 10.1097/QAI.0000000000000671.

3.

Outcomes after reinitiating antiretroviral therapy in children randomized to planned treatment interruptions.

Bunupuradah T, Duong T, Compagnucci A, McMaster P, Bernardi S, Kanjanavanit S, Rampon O, Faye A, Saïdi Y, Riault Y, De Rossi A, Klein N, Ananworanich J, Gibb D; PENTA 11 Extension Study Group.

AIDS. 2013 Feb 20;27(4):579-89. doi: 10.1097/QAD.0b013e32835c1181.

PMID:
23135172
4.

Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months.

Paediatric European Network for Treatment of AIDS (PENTA).

Antivir Ther. 2010;15(3):297-305. doi: 10.3851/IMP1532.

5.

Response to planned treatment interruptions in HIV infection varies across childhood.

Paediatric European Network for Treatment of AIDS.

AIDS. 2010 Jan 16;24(2):231-41. doi: 10.1097/QAD.0b013e328333d343.

PMID:
20010073
6.

PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection.

PENTA Steering Committee, Welch S, Sharland M, Lyall EG, Tudor-Williams G, Niehues T, Wintergerst U, Bunupuradah T, Hainaut M, Della Negra M, Pena MJ, Amador JT, Gattinara GC, Compagnucci A, Faye A, Giaquinto C, Gibb DM, Gandhi K, Forcat S, Buckberry K, Harper L, Königs C, Patel D, Bastiaans D.

HIV Med. 2009 Nov;10(10):591-613. doi: 10.1111/j.1468-1293.2009.00759.x.

7.

Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children.

Cressey TR, Green H, Khoo S, Treluyer JM, Compagnucci A, Saidi Y, Lallemant M, Gibb DM, Burger DM; Paediatric European Network for Treatment of AIDS II Study Group.

Clin Infect Dis. 2008 May 15;46(10):1601-8. doi: 10.1086/587657.

Supplemental Content

Loading ...
Support Center